Meloxicam市場報告：趨勢、預測與競爭分析（至2031年）

由於類風濕性關節炎、骨關節炎、軟組織發炎、創傷性疼痛和術後疼痛等領域的市場機會，全球Meloxicam市場前景廣闊。預計2025年至2031年，全球Meloxicam市場將以8.8%的年複合成長率成長。推動該市場成長的關鍵因素包括慢性發炎性疾病盛行率的上升、對非類固醇消炎劑（NSAIDs）需求的成長以及人們對疼痛管理解決方案日益成長的認知。

• 根據 Lucintel 的預測，依類型和劑型分類的市場預計將在預測期內呈現最高的成長率。
• 根據應用情況來看，類風濕性關節炎預計將呈現最高的成長率。
• 從區域來看，預計亞太地區在預測期內將達到最高的成長率。

Meloxicam市場的新趨勢

受對更精細化的患者照護的需求、對安全性的關注以及學名藥的普及的推動，Meloxicam市場經歷幾個新興趨勢，反映出從傳統口服片劑向更多樣化和更有針對性的製劑的轉變，以及對非鴉片類鎮痛解決方案的日益關注。

• 先進藥物遞送系統：一個顯著的趨勢是先進藥物遞送系統的開發，例如緩釋片和外用凝膠。這些創新目的是透過減少給藥頻率和最大限度地減少全身副作用（尤其是胃腸道不適）來提高患者的依從性。這為長期管理關節炎等慢性疾病提供了更方便、更安全的治療選擇。
• 非鴉片類鎮痛：一個關鍵趨勢是將Meloxicam定位為治療急性疼痛和術後疼痛的首選非鴉片類替代藥物。新型速效製劑，包括靜脈注射劑，已研發成功並核准，可在有效緩解疼痛的同時，避免鴉片類藥物相關的成癮風險和副作用。這一趨勢是對全球鴉片類藥物危機的直接回應。
• 非專利藥的成長：非專利洛昔康的日益普及持續影響著市場格局。隨著品牌藥專利到期，許多生產商推出了價格更低的替代產品。這一趨勢加劇了價格競爭，使更多患者能夠獲得Meloxicam，並擴大了其市場佔有率，尤其是在開發中國家。
• 聯合療法的進展：一種新興趨勢是基於Meloxicam的聯合療法的研究和開發，這種療法將Meloxicam與其他活性成分結合，以同時針對疼痛和發炎的多個方面。此類策略目的是提高治療效果，並提供更全面的治療方法，特別適用於複雜的發炎性疾病。
• 擴展至獸醫領域：Meloxicam在獸醫領域的應用日益廣泛，這是一個值得關注的趨勢。Meloxicam是一種安全有效的非類固醇消炎劑（NSAID），可用於治療伴侶動物和家畜的疼痛和發炎。隨著人們對獸醫領域的興趣日益濃厚，這個應用領域為市場開闢了新的成長途徑。

這些趨勢正從根本上重塑Meloxicam市場，其應用範圍已擴展至傳統關節炎治療之外，製劑也更加安全便捷，並透過學名藥競爭提高了產品的可及性。市場正朝著更專業、針對特定應用的產品方向發展，以滿足人類和動物醫療保健領域不斷變化的需求。

Meloxicam市場近期趨勢

在藥物傳遞技術的創新以及對患者安全和便利性的重視的推動下，Meloxicam市場經歷一系列關鍵發展，這些發展影響全球競爭格局和產品供應，目的是滿足不斷變化的醫療保健需求，尤其是在慢性疼痛管理和術後護理方面。

• 速效靜脈製劑：一項重要進展是，一種用於治療中重度急性疼痛的新型Meloxicam靜脈製劑核准並上市。這種速效非鴉片類注射製劑為術後疼痛管理提供了重要的替代方案，並有助於減少鴉片類藥物依賴。它的推出產生了顯著影響，尤其是在醫院環境中，快速起效非常重要。
• 緩釋片：另一個重要進展是Meloxicam緩釋性片的問世。這些製劑目的是每日一次給藥，即可提供長達24小時的持續鎮痛效果。這提高了患者的依從性，減少了給藥頻率，並最大限度地降低了胃腸道不適的風險，使其成為長期治療慢性關節炎的更便捷選擇。
• 學名藥競爭加劇：隨著關鍵專利的到期，市場學名藥競爭日益激烈。這降低了Meloxicam的平均價格，使其更加經濟實惠，並惠及更多患者。在對品牌藥價格帶來壓力的同時，學名藥的出現也擴大了該藥物的市場規模和整體使用率。
• 局部用凝膠：Meloxicam局部用凝膠的研發和上市是局部疼痛治療領域的重大進步。它可以直接塗抹於患處，提供針對性緩解，同時減少全身用藥及其相關副作用。這種劑型尤其適用於有特定關節骨關節炎等疾病的患者。
• 策略聯盟與收購：製藥公司正積極尋求策略聯盟與收購，以拓展其Meloxicam產品系列與地理覆蓋範圍。與非專利生產商和致力於新型藥物遞送技術的公司的合作，加速市場成長，促進創新，並幫助企業獲得競爭優勢。

這些發展正透過產品多樣化、提高病患安全性和便利性以及擴大市場進入，對Meloxicam市場產生重大影響。市場正從依賴傳統口服片劑轉向各種能夠滿足特定患者需求的製劑，從急性術後疼痛到慢性關節炎管理。

目錄

第1章 執行摘要

第2章 市場概覽

• 背景和分類
• 供應鏈

第3章 市場趨勢與預測分析

• 產業促進因素與挑戰
• PESTLE分析
• 專利分析
• 法規環境

第4章 全球Meloxicam市場（依類型）

• 吸引力分析：依類型
• 依成分
• 依途徑
• 依劑型

第5章 全球Meloxicam市場（依應用領域）

• 吸引力分析：依應用
• 類風濕性關節炎
• 骨關節炎
• 軟組織炎症
• 創傷性疼痛
• 術後疼痛
• 其他

第6章 區域分析

第7章 北美Meloxicam市場

• 北美Meloxicam市場（依類型）
• 北美Meloxicam市場（依應用領域）
• 美國Meloxicam市場
• 墨西哥Meloxicam市場
• 加拿大Meloxicam市場

第8章 歐洲Meloxicam市場

• 歐洲Meloxicam市場（依類型）
• 歐洲Meloxicam市場（依應用）
• 德國Meloxicam市場
• 法國Meloxicam市場
• 西班牙Meloxicam市場
• 義大利Meloxicam市場
• 英國Meloxicam市場

第9章 亞太地區Meloxicam市場

• 亞太地區Meloxicam市場（依類型）
• 亞太地區Meloxicam市場（依應用領域）
• 日本Meloxicam市場
• 印度Meloxicam市場
• 中國Meloxicam市場
• 韓國Meloxicam市場
• 印尼Meloxicam市場

第10章 世界其他地區（ROW）Meloxicam市場

• Meloxicam市場（依類型）
• Meloxicam市場（依應用領域）
• 中東Meloxicam市場
• 南美洲Meloxicam市場
• 非洲Meloxicam市場

第11章 競爭分析

• 產品系列分析
• 運作整合
• 波特五力分析
• 市場佔有率分析

第12章 機會與策略分析

• 價值鏈分析
• 成長機會分析
• 全球Meloxicam市場的新趨勢
• 戰略分析

第13章 價值鏈中主要企業的概況

• 競爭分析
• Boehringer Ingelheim
• Baudax
• Perrigo
• Recro Pharma
• Iroko Pharma
• Zyla Life Sciences
• Axsome Therapeutics
• Orbis Biosciences
• Cellix Bio
• Ligand Pharma

第14章 附錄

The future of the global meloxicam market looks promising with opportunities in the rheumatoid arthritis, osteoarthritis, soft tissue inflammation, traumatic pain, and post-operative pain markets. The global meloxicam market is expected to grow with a CAGR of 8.8% from 2025 to 2031. The major drivers for this market are the increasing prevalence of chronic inflammatory diseases, the rising demand for non-steroidal anti-inflammatory drugs, and the growing awareness of pain management solutions.

• Lucintel forecasts that, within the type category, by dosage form is expected to witness the highest growth over the forecast period.
• Within the application category, rheumatoid arthritis is expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Meloxicam Market

The meloxicam market is witnessing several emerging trends, which are driven by the need for enhanced patient care, a focus on safety, and the proliferation of generic alternatives. These trends reflect a shift from traditional oral tablets to more diverse and targeted formulations, as well as an increased focus on non-opioid pain management solutions.

• Advanced Drug Delivery Systems: A prominent trend is the development of advanced drug delivery systems, such as extended-release tablets and topical gels. These innovations aim to improve patient compliance by reducing dosing frequency and minimizing systemic side effects, particularly gastrointestinal issues. This provides a more convenient and safer treatment option for long-term management of chronic conditions like arthritis.
• Non-Opioid Pain Management: A key trend is the positioning of meloxicam as a primary non-opioid alternative for acute and post-operative pain. New fast-acting formulations, including intravenous injections, are being developed and approved to provide effective pain relief without the risks of addiction and side effects associated with opioids. This trend directly addresses the global opioid crisis.
• Growth of Generic Formulations: The market continues to be shaped by the increasing prevalence of generic meloxicam. Following the patent expiration of branded products, numerous manufacturers have introduced low-cost alternatives. This trend has intensified price competition, making meloxicam more accessible to a wider patient population and expanding its market share, especially in developing economies.
• Combination Therapies: Another emerging trend is the research and development of combination therapies involving meloxicam. This involves combining meloxicam with other active ingredients to target multiple aspects of pain and inflammation simultaneously. Such strategies aim to improve therapeutic outcomes and offer a more comprehensive treatment approach, particularly for complex inflammatory conditions.
• Expansion into Veterinary Medicine: A notable trend is the growing application of meloxicam in veterinary medicine. As a safe and effective non-steroidal anti-inflammatory drug (NSAID) for animals, meloxicam is increasingly used to manage pain and inflammation in companion animals and livestock. This application presents a new growth avenue for the market, driven by the increasing focus on animal health.

These trends are fundamentally reshaping the meloxicam market by expanding its applications beyond traditional arthritis treatment, offering safer and more convenient formulations, and increasing accessibility through generic competition. The market is moving towards more specialized, application-specific products that cater to the evolving needs of both human and veterinary healthcare.

Recent Developments in the Meloxicam Market

The meloxicam market has seen a number of key developments driven by innovations in drug delivery and a strong focus on patient safety and convenience. These advancements are aimed at addressing evolving healthcare needs, particularly in chronic pain management and post-operative care, and are impacting the competitive landscape and product offerings globally.

• Fast-Acting IV Formulation: A significant development is the approval and market availability of a new intravenous (IV) formulation of meloxicam for moderate-to-severe acute pain. This fast-acting non-opioid injectable offers a crucial alternative for post-surgical pain management, helping to reduce reliance on opioids. Its introduction is particularly impactful in hospital settings, where a rapid onset of action is essential.
• Extended-Release Tablets: Another key development is the introduction of extended-release meloxicam tablets. These formulations are designed to provide sustained pain relief over a 24-hour period with a single daily dose. This improves patient adherence, reduces dosing frequency, and helps to minimize the risk of gastrointestinal side effects, making it a more convenient option for long-term management of chronic arthritis.
• Growing Generic Competition: The market has experienced a surge in generic competition following the expiration of key patents. This development has led to a reduction in the average price of meloxicam, making it more affordable and accessible to a wider patient population. While this puts pressure on the pricing of branded products, it also drives market volume and expands the drug's overall use.
• Topical Gels for Localized Pain: The development and introduction of topical meloxicam gels represent a significant advancement for treating localized pain. These gels allow for direct application to the affected area, providing targeted relief while reducing systemic exposure and the associated side effects. This formulation is particularly beneficial for patients with conditions like osteoarthritis in specific joints.
• Strategic Partnerships and Acquisitions: Pharmaceutical companies are engaging in strategic partnerships and acquisitions to expand their meloxicam product portfolios and geographical reach. These collaborations, particularly with generic manufacturers and companies specializing in new drug delivery technologies, are accelerating market growth, fostering innovation, and helping companies to gain a competitive edge.

These developments are having a profound impact on the meloxicam market by diversifying product offerings, enhancing patient safety and convenience, and increasing market accessibility. The market is shifting from a reliance on traditional oral tablets to a more diverse range of formulations that cater to specific patient needs, from acute post-operative pain to chronic arthritis management.

Strategic Growth Opportunities in the Meloxicam Market

The meloxicam market offers several strategic growth opportunities, driven by its versatile applications and the increasing demand for effective, non-opioid pain management solutions. These opportunities are focused on expanding into new therapeutic areas, developing innovative formulations, and catering to specific patient populations, thereby enhancing market penetration and value.

• Post-Operative Pain Management: A significant growth opportunity lies in positioning meloxicam as a first-line non-opioid alternative for post-operative pain. The development of fast-acting intravenous formulations allows for immediate pain relief in a clinical setting, reducing the need for addictive opioids. This is a high-growth area, driven by global efforts to mitigate the opioid crisis.
• Topical Formulations for Arthritis: The growing demand for non-systemic treatments for localized pain presents a key opportunity for topical meloxicam gels and creams. These formulations can provide targeted relief for conditions like osteoarthritis, minimizing the risk of systemic side effects. This application addresses a large patient population seeking a safer alternative to oral NSAIDs.
• Combination Therapies for Chronic Pain: Developing meloxicam-based combination therapies offers a strategic opportunity to create more potent and comprehensive pain management solutions. By combining meloxicam with other analgesics or anti-inflammatory agents, companies can offer multi-modal pain relief, which is particularly effective for managing chronic conditions that do not respond to a single medication.
• Veterinary Applications: The veterinary pharmaceutical sector represents a promising growth opportunity for meloxicam. As pet ownership and animal healthcare expenditure rise, there is increasing demand for effective and safe pain and inflammation management in animals. Meloxicam's established efficacy makes it a strong candidate for this expanding market segment.
• Formulations for Pediatrics: A niche but important opportunity exists in developing pediatric-specific meloxicam formulations. With the approval of meloxicam for juvenile rheumatoid arthritis, there is a need for child-friendly dosage forms, such as suspensions or chewable tablets. This would address a significant unmet need and expand the drug's market to a younger patient population.

These growth opportunities are impacting the meloxicam market by driving innovation beyond its traditional use. By focusing on these strategic areas, companies can differentiate their products, capture new market segments, and ultimately solidify meloxicam's position as a versatile and essential non-opioid medication in a wide range of applications.

Meloxicam Market Driver and Challenges

The meloxicam market is a dynamic landscape shaped by various drivers that propel its growth and a set of challenges that can hinder its progress. The key drivers are rooted in global demographic shifts and the pressing need for safer pain management, while challenges arise from regulatory scrutiny and intense market competition.

The factors responsible for driving the meloxicam market include:

1. Rising Prevalence of Arthritis: The increasing global prevalence of osteoarthritis and rheumatoid arthritis, particularly among the aging population, is a primary driver. Meloxicam is a widely prescribed NSAID for these conditions, and as the number of patients grows, so does the demand for the drug. This demographic shift provides a solid foundation for market expansion.

2. Preference for Non-Opioid Pain Relief: A major driver is the global effort to combat the opioid crisis. Healthcare providers and patients are increasingly seeking effective non-opioid alternatives for both chronic and acute pain management. Meloxicam, with its established efficacy and favorable safety profile compared to opioids, is well-positioned to meet this demand.

3. Patent Expirations and Generic Growth: The expiration of key patents has led to a proliferation of generic meloxicam products. This has made the drug more affordable and accessible, particularly in emerging markets. The resulting increase in market volume and competition is a significant driver of overall market growth.

4. Technological Advancements: Innovations in drug delivery systems, such as extended-release and intravenous formulations, are driving market growth. These advancements improve patient convenience, efficacy, and safety, making meloxicam a more attractive option for a wider range of applications, including post-operative care.

5. Growing Healthcare Expenditure: The rise in global healthcare expenditure, particularly in emerging economies, is a key driver. Increased spending allows for better access to medications and advanced treatments, thereby boosting the demand for meloxicam and other anti-inflammatory drugs.

Challenges in the meloxicam market are:

1. Side Effect Profile: Meloxicam, like all NSAIDs, carries a risk of side effects, including gastrointestinal and cardiovascular issues. These safety concerns can limit its use in certain patient populations and necessitate careful monitoring, which poses a significant challenge to market growth.

2. Competition from Alternatives: The market is highly competitive, not only from generic versions of meloxicam but also from other NSAIDs, biologics, and novel pain therapies. Differentiating meloxicam and its new formulations in a crowded market and maintaining market share is a continuous challenge for manufacturers.

3. Strict Regulatory Environment: The development and approval of new meloxicam formulations face a stringent regulatory environment. Regulatory bodies require extensive clinical data to prove efficacy and safety, which can be a costly and time-consuming process. This creates a barrier to entry for new products and slows down innovation.

The meloxicam market is being propelled by the growing need for effective, safe, and affordable pain management solutions, driven by an aging population and the fight against the opioid crisis. However, these positive trends are tempered by the inherent safety concerns associated with NSAIDs, intense market competition, and the challenging regulatory landscape that new formulations must navigate to reach the market.

List of Meloxicam Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies meloxicam companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the meloxicam companies profiled in this report include-

• Boehringer Ingelheim
• Baudax
• Perrigo
• Recro Pharma
• Iroko Pharma
• Zyla Life Sciences
• Axsome Therapeutics
• Orbis Biosciences
• Cellix Bio
• Ligand Pharma

Meloxicam Market by Segment

The study includes a forecast for the global meloxicam market by type, application, and region.

Meloxicam Market by Type [Value from 2019 to 2031]:

• by Ingredient
• by Route
• by Dosage Form

Meloxicam Market by Application [Value from 2019 to 2031]:

• Rheumatoid Arthritis
• Osteoarthritis
• Soft Tissue Inflammation
• Traumatic Pain
• Post-Operative Pain
• Others

Country Wise Outlook for the Meloxicam Market

The meloxicam market is undergoing significant transformations, driven by a growing aging population and rising prevalence of chronic inflammatory conditions like osteoarthritis and rheumatoid arthritis. This has spurred a shift towards new formulations and a greater emphasis on non-opioid pain management. The market is also heavily influenced by generic competition and regional regulatory dynamics, shaping pricing and market access globally.

• United States: The U.S. market is highly competitive, with a strong presence of both branded and generic meloxicam. A key development is the focus on new, fast-acting formulations, such as those for intravenous use, aimed at managing moderate-to-severe acute pain. These innovations offer a non-opioid alternative for post-operative care, addressing the national opioid crisis and meeting demand for safer pain management.
• China: The Chinese meloxicam market is experiencing rapid growth, fueled by the country's expanding healthcare infrastructure and a large, aging population. Local and international companies are increasing their presence, with a focus on producing and distributing cost-effective generic versions. This expansion is supported by government initiatives to improve healthcare access and manage the rising burden of chronic diseases.
• Germany: Germany represents a mature European market for meloxicam, characterized by a well-established healthcare system and a strong emphasis on quality and safety. The market is driven by the management of chronic conditions, with a steady demand for both oral and injectable formulations. Regulatory standards and reimbursement policies play a crucial role in shaping market dynamics and product availability.
• India: India is a fast-growing market, primarily dominated by generic meloxicam products due to their affordability. The market is propelled by a large patient base with inflammatory conditions and a growing middle class with increasing access to healthcare. Pharmaceutical companies are focusing on low-cost manufacturing and expanding their distribution networks to cater to this high-demand, price-sensitive market.
• Japan: The Japanese market is defined by its focus on technological advancements and high-quality pharmaceutical products. While the market for meloxicam is steady, there is a strong emphasis on developing and utilizing advanced drug delivery systems and formulations to improve efficacy and reduce side effects. This reflects Japan's patient-centric approach to healthcare and its advanced geriatric care needs.

Features of the Global Meloxicam Market

• Market Size Estimates: Meloxicam market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Meloxicam market size by type, application, and region in terms of value ($B).
• Regional Analysis: Meloxicam market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the meloxicam market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the meloxicam market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the meloxicam market by type (by ingredient, by route, and by dosage form), application (rheumatoid arthritis, osteoarthritis, soft tissue inflammation, traumatic pain, post-operative pain, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Meloxicam Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 by Ingredient: Trends and Forecast (2019-2031)
• 4.4 by Route: Trends and Forecast (2019-2031)
• 4.5 by Dosage Form: Trends and Forecast (2019-2031)

5. Global Meloxicam Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Rheumatoid Arthritis: Trends and Forecast (2019-2031)
• 5.4 Osteoarthritis: Trends and Forecast (2019-2031)
• 5.5 Soft Tissue Inflammation: Trends and Forecast (2019-2031)
• 5.6 Traumatic Pain: Trends and Forecast (2019-2031)
• 5.7 Post-Operative Pain: Trends and Forecast (2019-2031)
• 5.8 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Meloxicam Market by Region

7. North American Meloxicam Market

• 7.1 Overview
• 7.2 North American Meloxicam Market by Type
• 7.3 North American Meloxicam Market by Application
• 7.4 United States Meloxicam Market
• 7.5 Mexican Meloxicam Market
• 7.6 Canadian Meloxicam Market

8. European Meloxicam Market

• 8.1 Overview
• 8.2 European Meloxicam Market by Type
• 8.3 European Meloxicam Market by Application
• 8.4 German Meloxicam Market
• 8.5 French Meloxicam Market
• 8.6 Spanish Meloxicam Market
• 8.7 Italian Meloxicam Market
• 8.8 United Kingdom Meloxicam Market

9. APAC Meloxicam Market

• 9.1 Overview
• 9.2 APAC Meloxicam Market by Type
• 9.3 APAC Meloxicam Market by Application
• 9.4 Japanese Meloxicam Market
• 9.5 Indian Meloxicam Market
• 9.6 Chinese Meloxicam Market
• 9.7 South Korean Meloxicam Market
• 9.8 Indonesian Meloxicam Market

10. ROW Meloxicam Market

• 10.1 Overview
• 10.2 ROW Meloxicam Market by Type
• 10.3 ROW Meloxicam Market by Application
• 10.4 Middle Eastern Meloxicam Market
• 10.5 South American Meloxicam Market
• 10.6 African Meloxicam Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Meloxicam Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Boehringer Ingelheim
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Baudax
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Perrigo
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Recro Pharma
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Iroko Pharma
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Zyla Life Sciences
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Axsome Therapeutics
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 Orbis Biosciences
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 Cellix Bio
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Ligand Pharma
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us

List of Figures

• Figure 1.1: Trends and Forecast for the Global Meloxicam Market
• Figure 2.1: Usage of Meloxicam Market
• Figure 2.2: Classification of the Global Meloxicam Market
• Figure 2.3: Supply Chain of the Global Meloxicam Market
• Figure 3.1: Driver and Challenges of the Meloxicam Market
• Figure 3.2: PESTLE Analysis
• Figure 3.3: Patent Analysis
• Figure 3.4: Regulatory Environment
• Figure 4.1: Global Meloxicam Market by Type in 2019, 2024, and 2031
• Figure 4.2: Trends of the Global Meloxicam Market ($B) by Type
• Figure 4.3: Forecast for the Global Meloxicam Market ($B) by Type
• Figure 4.4: Trends and Forecast for by Ingredient in the Global Meloxicam Market (2019-2031)
• Figure 4.5: Trends and Forecast for by Route in the Global Meloxicam Market (2019-2031)
• Figure 4.6: Trends and Forecast for by Dosage Form in the Global Meloxicam Market (2019-2031)
• Figure 5.1: Global Meloxicam Market by Application in 2019, 2024, and 2031
• Figure 5.2: Trends of the Global Meloxicam Market ($B) by Application
• Figure 5.3: Forecast for the Global Meloxicam Market ($B) by Application
• Figure 5.4: Trends and Forecast for Rheumatoid Arthritis in the Global Meloxicam Market (2019-2031)
• Figure 5.5: Trends and Forecast for Osteoarthritis in the Global Meloxicam Market (2019-2031)
• Figure 5.6: Trends and Forecast for Soft Tissue Inflammation in the Global Meloxicam Market (2019-2031)
• Figure 5.7: Trends and Forecast for Traumatic Pain in the Global Meloxicam Market (2019-2031)
• Figure 5.8: Trends and Forecast for Post-Operative Pain in the Global Meloxicam Market (2019-2031)
• Figure 5.9: Trends and Forecast for Others in the Global Meloxicam Market (2019-2031)
• Figure 6.1: Trends of the Global Meloxicam Market ($B) by Region (2019-2024)
• Figure 6.2: Forecast for the Global Meloxicam Market ($B) by Region (2025-2031)
• Figure 7.1: North American Meloxicam Market by Type in 2019, 2024, and 2031
• Figure 7.2: Trends of the North American Meloxicam Market ($B) by Type (2019-2024)
• Figure 7.3: Forecast for the North American Meloxicam Market ($B) by Type (2025-2031)
• Figure 7.4: North American Meloxicam Market by Application in 2019, 2024, and 2031
• Figure 7.5: Trends of the North American Meloxicam Market ($B) by Application (2019-2024)
• Figure 7.6: Forecast for the North American Meloxicam Market ($B) by Application (2025-2031)
• Figure 7.7: Trends and Forecast for the United States Meloxicam Market ($B) (2019-2031)
• Figure 7.8: Trends and Forecast for the Mexican Meloxicam Market ($B) (2019-2031)
• Figure 7.9: Trends and Forecast for the Canadian Meloxicam Market ($B) (2019-2031)
• Figure 8.1: European Meloxicam Market by Type in 2019, 2024, and 2031
• Figure 8.2: Trends of the European Meloxicam Market ($B) by Type (2019-2024)
• Figure 8.3: Forecast for the European Meloxicam Market ($B) by Type (2025-2031)
• Figure 8.4: European Meloxicam Market by Application in 2019, 2024, and 2031
• Figure 8.5: Trends of the European Meloxicam Market ($B) by Application (2019-2024)
• Figure 8.6: Forecast for the European Meloxicam Market ($B) by Application (2025-2031)
• Figure 8.7: Trends and Forecast for the German Meloxicam Market ($B) (2019-2031)
• Figure 8.8: Trends and Forecast for the French Meloxicam Market ($B) (2019-2031)
• Figure 8.9: Trends and Forecast for the Spanish Meloxicam Market ($B) (2019-2031)
• Figure 8.10: Trends and Forecast for the Italian Meloxicam Market ($B) (2019-2031)
• Figure 8.11: Trends and Forecast for the United Kingdom Meloxicam Market ($B) (2019-2031)
• Figure 9.1: APAC Meloxicam Market by Type in 2019, 2024, and 2031
• Figure 9.2: Trends of the APAC Meloxicam Market ($B) by Type (2019-2024)
• Figure 9.3: Forecast for the APAC Meloxicam Market ($B) by Type (2025-2031)
• Figure 9.4: APAC Meloxicam Market by Application in 2019, 2024, and 2031
• Figure 9.5: Trends of the APAC Meloxicam Market ($B) by Application (2019-2024)
• Figure 9.6: Forecast for the APAC Meloxicam Market ($B) by Application (2025-2031)
• Figure 9.7: Trends and Forecast for the Japanese Meloxicam Market ($B) (2019-2031)
• Figure 9.8: Trends and Forecast for the Indian Meloxicam Market ($B) (2019-2031)
• Figure 9.9: Trends and Forecast for the Chinese Meloxicam Market ($B) (2019-2031)
• Figure 9.10: Trends and Forecast for the South Korean Meloxicam Market ($B) (2019-2031)
• Figure 9.11: Trends and Forecast for the Indonesian Meloxicam Market ($B) (2019-2031)
• Figure 10.1: ROW Meloxicam Market by Type in 2019, 2024, and 2031
• Figure 10.2: Trends of the ROW Meloxicam Market ($B) by Type (2019-2024)
• Figure 10.3: Forecast for the ROW Meloxicam Market ($B) by Type (2025-2031)
• Figure 10.4: ROW Meloxicam Market by Application in 2019, 2024, and 2031
• Figure 10.5: Trends of the ROW Meloxicam Market ($B) by Application (2019-2024)
• Figure 10.6: Forecast for the ROW Meloxicam Market ($B) by Application (2025-2031)
• Figure 10.7: Trends and Forecast for the Middle Eastern Meloxicam Market ($B) (2019-2031)
• Figure 10.8: Trends and Forecast for the South American Meloxicam Market ($B) (2019-2031)
• Figure 10.9: Trends and Forecast for the African Meloxicam Market ($B) (2019-2031)
• Figure 11.1: Porter's Five Forces Analysis of the Global Meloxicam Market
• Figure 11.2: Market Share (%) of Top Players in the Global Meloxicam Market (2024)
• Figure 12.1: Growth Opportunities for the Global Meloxicam Market by Type
• Figure 12.2: Growth Opportunities for the Global Meloxicam Market by Application
• Figure 12.3: Growth Opportunities for the Global Meloxicam Market by Region
• Figure 12.4: Emerging Trends in the Global Meloxicam Market

List of Tables

• Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Meloxicam Market by Type and Application
• Table 1.2: Attractiveness Analysis for the Meloxicam Market by Region
• Table 1.3: Global Meloxicam Market Parameters and Attributes
• Table 3.1: Trends of the Global Meloxicam Market (2019-2024)
• Table 3.2: Forecast for the Global Meloxicam Market (2025-2031)
• Table 4.1: Attractiveness Analysis for the Global Meloxicam Market by Type
• Table 4.2: Market Size and CAGR of Various Type in the Global Meloxicam Market (2019-2024)
• Table 4.3: Market Size and CAGR of Various Type in the Global Meloxicam Market (2025-2031)
• Table 4.4: Trends of by Ingredient in the Global Meloxicam Market (2019-2024)
• Table 4.5: Forecast for by Ingredient in the Global Meloxicam Market (2025-2031)
• Table 4.6: Trends of by Route in the Global Meloxicam Market (2019-2024)
• Table 4.7: Forecast for by Route in the Global Meloxicam Market (2025-2031)
• Table 4.8: Trends of by Dosage Form in the Global Meloxicam Market (2019-2024)
• Table 4.9: Forecast for by Dosage Form in the Global Meloxicam Market (2025-2031)
• Table 5.1: Attractiveness Analysis for the Global Meloxicam Market by Application
• Table 5.2: Market Size and CAGR of Various Application in the Global Meloxicam Market (2019-2024)
• Table 5.3: Market Size and CAGR of Various Application in the Global Meloxicam Market (2025-2031)
• Table 5.4: Trends of Rheumatoid Arthritis in the Global Meloxicam Market (2019-2024)
• Table 5.5: Forecast for Rheumatoid Arthritis in the Global Meloxicam Market (2025-2031)
• Table 5.6: Trends of Osteoarthritis in the Global Meloxicam Market (2019-2024)
• Table 5.7: Forecast for Osteoarthritis in the Global Meloxicam Market (2025-2031)
• Table 5.8: Trends of Soft Tissue Inflammation in the Global Meloxicam Market (2019-2024)
• Table 5.9: Forecast for Soft Tissue Inflammation in the Global Meloxicam Market (2025-2031)
• Table 5.10: Trends of Traumatic Pain in the Global Meloxicam Market (2019-2024)
• Table 5.11: Forecast for Traumatic Pain in the Global Meloxicam Market (2025-2031)
• Table 5.12: Trends of Post-Operative Pain in the Global Meloxicam Market (2019-2024)
• Table 5.13: Forecast for Post-Operative Pain in the Global Meloxicam Market (2025-2031)
• Table 5.14: Trends of Others in the Global Meloxicam Market (2019-2024)
• Table 5.15: Forecast for Others in the Global Meloxicam Market (2025-2031)
• Table 6.1: Market Size and CAGR of Various Regions in the Global Meloxicam Market (2019-2024)
• Table 6.2: Market Size and CAGR of Various Regions in the Global Meloxicam Market (2025-2031)
• Table 7.1: Trends of the North American Meloxicam Market (2019-2024)
• Table 7.2: Forecast for the North American Meloxicam Market (2025-2031)
• Table 7.3: Market Size and CAGR of Various Type in the North American Meloxicam Market (2019-2024)
• Table 7.4: Market Size and CAGR of Various Type in the North American Meloxicam Market (2025-2031)
• Table 7.5: Market Size and CAGR of Various Application in the North American Meloxicam Market (2019-2024)
• Table 7.6: Market Size and CAGR of Various Application in the North American Meloxicam Market (2025-2031)
• Table 7.7: Trends and Forecast for the United States Meloxicam Market (2019-2031)
• Table 7.8: Trends and Forecast for the Mexican Meloxicam Market (2019-2031)
• Table 7.9: Trends and Forecast for the Canadian Meloxicam Market (2019-2031)
• Table 8.1: Trends of the European Meloxicam Market (2019-2024)
• Table 8.2: Forecast for the European Meloxicam Market (2025-2031)
• Table 8.3: Market Size and CAGR of Various Type in the European Meloxicam Market (2019-2024)
• Table 8.4: Market Size and CAGR of Various Type in the European Meloxicam Market (2025-2031)
• Table 8.5: Market Size and CAGR of Various Application in the European Meloxicam Market (2019-2024)
• Table 8.6: Market Size and CAGR of Various Application in the European Meloxicam Market (2025-2031)
• Table 8.7: Trends and Forecast for the German Meloxicam Market (2019-2031)
• Table 8.8: Trends and Forecast for the French Meloxicam Market (2019-2031)
• Table 8.9: Trends and Forecast for the Spanish Meloxicam Market (2019-2031)
• Table 8.10: Trends and Forecast for the Italian Meloxicam Market (2019-2031)
• Table 8.11: Trends and Forecast for the United Kingdom Meloxicam Market (2019-2031)
• Table 9.1: Trends of the APAC Meloxicam Market (2019-2024)
• Table 9.2: Forecast for the APAC Meloxicam Market (2025-2031)
• Table 9.3: Market Size and CAGR of Various Type in the APAC Meloxicam Market (2019-2024)
• Table 9.4: Market Size and CAGR of Various Type in the APAC Meloxicam Market (2025-2031)
• Table 9.5: Market Size and CAGR of Various Application in the APAC Meloxicam Market (2019-2024)
• Table 9.6: Market Size and CAGR of Various Application in the APAC Meloxicam Market (2025-2031)
• Table 9.7: Trends and Forecast for the Japanese Meloxicam Market (2019-2031)
• Table 9.8: Trends and Forecast for the Indian Meloxicam Market (2019-2031)
• Table 9.9: Trends and Forecast for the Chinese Meloxicam Market (2019-2031)
• Table 9.10: Trends and Forecast for the South Korean Meloxicam Market (2019-2031)
• Table 9.11: Trends and Forecast for the Indonesian Meloxicam Market (2019-2031)
• Table 10.1: Trends of the ROW Meloxicam Market (2019-2024)
• Table 10.2: Forecast for the ROW Meloxicam Market (2025-2031)
• Table 10.3: Market Size and CAGR of Various Type in the ROW Meloxicam Market (2019-2024)
• Table 10.4: Market Size and CAGR of Various Type in the ROW Meloxicam Market (2025-2031)
• Table 10.5: Market Size and CAGR of Various Application in the ROW Meloxicam Market (2019-2024)
• Table 10.6: Market Size and CAGR of Various Application in the ROW Meloxicam Market (2025-2031)
• Table 10.7: Trends and Forecast for the Middle Eastern Meloxicam Market (2019-2031)
• Table 10.8: Trends and Forecast for the South American Meloxicam Market (2019-2031)
• Table 10.9: Trends and Forecast for the African Meloxicam Market (2019-2031)
• Table 11.1: Product Mapping of Meloxicam Suppliers Based on Segments
• Table 11.2: Operational Integration of Meloxicam Manufacturers
• Table 11.3: Rankings of Suppliers Based on Meloxicam Revenue
• Table 12.1: New Product Launches by Major Meloxicam Producers (2019-2024)
• Table 12.2: Certification Acquired by Major Competitor in the Global Meloxicam Market